167 related articles for article (PubMed ID: 7796678)
1. Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.
Melief CJ; Kast WM
Ciba Found Symp; 1994; 187():97-104; discussion 104-12. PubMed ID: 7796678
[TBL] [Abstract][Full Text] [Related]
2. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
Melief CJ; Kast WM
Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
[TBL] [Abstract][Full Text] [Related]
3. Can one predict antigenic peptides for MHC class I-restricted cytotoxic T lymphocytes useful for vaccination?
Calin-Laurens V; Trescol-Biémont MC; Gerlier D; Rabourdin-Combe C
Vaccine; 1993; 11(9):974-8. PubMed ID: 7692684
[TBL] [Abstract][Full Text] [Related]
4. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
[TBL] [Abstract][Full Text] [Related]
5. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
[TBL] [Abstract][Full Text] [Related]
6. The recognition of a viral antigenic moiety by class I MHC-restricted cytolytic T lymphocytes is limited by the availability of the endogenously processed antigen.
Milligan GN; Morrison LA; Gorka J; Braciale VL; Braciale TJ
J Immunol; 1990 Nov; 145(10):3188-93. PubMed ID: 1700000
[TBL] [Abstract][Full Text] [Related]
7. Interaction of in vitro- and in vivo-generated cytotoxic T cells with SV40 T antigen: analysis with synthetic peptides.
Alsheikhly AR
Scand J Immunol; 1994 May; 39(5):467-79. PubMed ID: 8191222
[TBL] [Abstract][Full Text] [Related]
8. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity.
Feltkamp MC; Vierboom MP; Kast WM; Melief CJ
Mol Immunol; 1994 Dec; 31(18):1391-401. PubMed ID: 7823965
[TBL] [Abstract][Full Text] [Related]
9. Immunization with dendritic cells breaks immunodominance in CTL responses against minor histocompatibility and synthetic peptide antigens.
Grufman P; Sandberg JK; Wolpert EZ; Kärre K
J Leukoc Biol; 1999 Aug; 66(2):268-71. PubMed ID: 10449165
[TBL] [Abstract][Full Text] [Related]
10. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.
Lipford GB; Bauer S; Wagner H; Heeg K
Immunology; 1995 Feb; 84(2):298-303. PubMed ID: 7751006
[TBL] [Abstract][Full Text] [Related]
11. In vivo CTL immunity can be elicited by in vitro reconstituted MHC/peptide complex.
Sakita I; Hörig H; Sun R; Wang F; Nathenson SG
J Immunol Methods; 1996 Jun; 192(1-2):105-15. PubMed ID: 8699005
[TBL] [Abstract][Full Text] [Related]
12. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.
Huang AY; Gulden PH; Woods AS; Thomas MC; Tong CD; Wang W; Engelhard VH; Pasternack G; Cotter R; Hunt D; Pardoll DM; Jaffee EM
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9730-5. PubMed ID: 8790399
[TBL] [Abstract][Full Text] [Related]
13. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope.
Vierboom MP; Feltkamp MC; Neisig A; Drijfhout JW; ter Schegget J; Neefjes JJ; Melief CJ; Kast WM
J Immunother; 1998 Nov; 21(6):399-408. PubMed ID: 9807734
[TBL] [Abstract][Full Text] [Related]
14. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
15. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
16. Self-veto mechanism of CD8+ cytotoxic effector T cells. Peptide-induced paralysis affects the peptide-MHC-recognizing cytotoxic T lymphocytes and is independent of Fas/Fas ligand interactions.
Bergenthal A; Hofmann M; Heeg K
Eur J Immunol; 1998 Jun; 28(6):1911-22. PubMed ID: 9645373
[TBL] [Abstract][Full Text] [Related]
17. Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization.
Feltkamp MC; Vierboom MP; Toes RE; Ossendorp F; ter Schegget J; Melief CJ; Kast WM
Immunol Lett; 1995; 47(1-2):1-8. PubMed ID: 8537084
[TBL] [Abstract][Full Text] [Related]
18. Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-MHC binding.
Kast WM; Melief CJ
Int J Cancer Suppl; 1991; 6():90-4. PubMed ID: 2066186
[TBL] [Abstract][Full Text] [Related]
19. MHC class I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses.
Pamer EG; Sijts AJ; Villanueva MS; Busch DH; Vijh S
Immunol Rev; 1997 Aug; 158():129-36. PubMed ID: 9314081
[TBL] [Abstract][Full Text] [Related]
20. Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes.
Levitsky V; Zhang QJ; Levitskaya J; Kurilla MG; Masucci MG
J Immunol; 1997 Dec; 159(11):5383-90. PubMed ID: 9548478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
